Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 120,804 Shares

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc purchased 120,804 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was bought at an average cost of $13.97 per share, for a total transaction of $1,687,631.88. Following the completion of the purchase, the insider directly owned 744,683 shares in the company, valued at $10,403,221.51. This represents a 19.36% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The stock was bought at an average cost of $14.00 per share, for a total transaction of $491,414.00.

Rallybio Price Performance

Rallybio stock traded up $0.28 during midday trading on Wednesday, reaching $14.56. The company had a trading volume of 238,233 shares, compared to its average volume of 611,199. The company has a market capitalization of $77.02 million, a P/E ratio of -5.69 and a beta of -1.10. Rallybio Corporation has a 12-month low of $2.16 and a 12-month high of $15.31. The firm’s fifty day simple moving average is $9.01 and its 200-day simple moving average is $6.58.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings results on Monday, March 16th. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.01. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.10 million. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Rallybio to a “hold” rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Rallybio has a consensus rating of “Sell”.

Institutional Trading of Rallybio

Hedge funds have recently bought and sold shares of the business. XTX Topco Ltd raised its holdings in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the last quarter. Susquehanna International Group LLP raised its holdings in Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares during the last quarter. Geode Capital Management LLC raised its holdings in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after acquiring an additional 2,996 shares during the last quarter. Citadel Advisors LLC raised its holdings in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after acquiring an additional 120,892 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.